AlgoTherapeutix (AlgoTx) is a clinical stage biotechnology company developing targeted, first in class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors through a topical formulation. The company’s two lead indications are Chemotherapy-Induced Peripheral Neuropathy (CIPN), caused by nerve damage as a common side effect of cancer treatment, and Erythromelalgia (EM), a rare disease characterized notably by burning pain in the extremities.

TEAM

The company has seasoned leadership, with experience of bringing global products successfully to market, and is backed by an international board.

Squiggle Graphic
INVESTORS
Squiggle Graphic
ESG
award

In March 2023, at France Biotech’s prestigious HealthTech Trophies Ceremony, AlgoTx was awarded the 2023 ESG HealthTech Trophy in recognition of the biotech’s early commitment to ESG initiatives. Despite its young age, AlgoTx has been steadily supporting two NGOs: The social recycling movement Plastic Bank which gathers plastic on the shores around the world, and Gribouilli which helps precarious childcare workers around Paris develop a professional profile and activity.